Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study.
796 Background: Sacituzumab tirumotecan (sac-TMT; also known as MK-2870/SKB264) is a TROP2 targeting ADC with a hydrolytically cleavable linker and a topo...
Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.
99 Background: While androgen deprivation therapy (ADT) is a backbone for managing mHSPC, therapies initially approved for mCRPC, such as androgen recepto...
Association of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition.
401 Background: Patients diagnosed with localized high-risk PC have higher rates of recurrence, and neoadjuvant intensive hormonal therapies seek to treat...
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.
148 Background: Enzalutamide is a potent androgen receptor signal inhibitor used in the treatment of various stages of prostate cancer. However, treatment...
Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI).
818 Background: MSI-high (MSI-H) and dMMR are three times more common in UTUC than bladder cancer. While these features enhance ICI sensitivity in solid t...
Patient and caregiver preferences for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a targeted literature review (TLR).
755 Background: The treatment landscape for la/mUC has evolved with multiple care options available. As new therapies are adopted, decision-making among p...
Impact of concomitant medication use on treatment outcomes in patients with RCC treated with immune checkpoint inhibitors.
603 Background: Multiple studies on various cancer types have investigated concomitant statin, aspirin, and metformin use with immune checkpoint inhibitor...
Rates of first next-generation sequencing (NGS) testing at the end of life in patients (pts) with advanced urothelial carcinoma (aUC).
727 Background: Despite the availability of targeted therapies like erdafitinib for pts with aUC with susceptible genomic alterations, the rate of NGS tes...
A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.
TPS652 Background: Claudin-6 (CLDN6) is overexpressed in solid tumors including germ cell tumors (GCTs) with minimal expression in healthy tissue. This di...
Real-world effectiveness and safety of first-line (1L) avelumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.
474 Background: In the JAVELIN Renal 101 phase 3 trial, 1L avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a high...
Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).
17 Background: Interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival (PFS) and depth of PSA-response wi...
Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of <sup>177</sup> Lu-PSMA-617.
16 Background: In PSMAfore (NCT04689828), [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) prolonged rPFS versus an...
The role of salvage cystectomy after prior trimodality therapy.
781 Background: Trimodality therapy (TMT) with transurethral resection followed by radiation of the urinary bladder and chemotherapy is associated with si...
Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma.
639 Background: Surgical resection of post-chemotherapy residual masses for metastatic seminoma is discussed controversial...
Optimizing treatment approaches in nested bladder tumors: A multicenter retrospective study.
743 Background: Identifying optimal treatment strategies in nested bladder tumors is critical. This multicenter study aims at evaluating progression-free...
Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC).
770 Background: EVP is a preferred 1st-line option for patients (pts) with la/m UC. We sought to understand how genitourinary (GU) medical oncologists in...
Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.
399 Background: The three-arm randomized SPPORT trial (n=1792) examined the effect of treatment intensification on the outcome of men treated with salvage...
Understanding incidence and outcomes of testicular and ovarian germ cell tumors from 2000–2017 using population-based cancer registries.
649 Background: Both testicular (TGCT) and ovarian germ cell tumors (OGCT) originate from a common primordial germ cell lineage prior to differentiation i...
Outcomes of immune-checkpoint inhibitor rechallenge in urothelial carcinoma: Results from a global real-world evidence study.
732 Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of urothelial carcinoma (UC) across clinical stages. Sev...
Assess the journey: Characterizing muscle-invasive bladder cancer patients who receive neoadjuvant therapy and do not proceed with cystectomy.
746 Background: The standard treatment of muscle invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), off...
Prevalence of germline variants of uncertain significance in DNA repair genes and their potential impact on prostate cancer outcomes following radical prostatectomy.
421 Background: Pathogenic variants (PVs) in DNA repair genes (DRG) are linked to a higher risk of aggressive prostate cancer (PCa). Understanding and man...
Validation of navigator-assisted hypofractionation (NAVAH) program surveys in African-American prostate cancer patients.
313 Background: Prostate cancer is a leading cause of malignancy and death in men. African-Americans have the highest overall cancer death rate and shorte...
Impact of renal cell cancer histology on outcomes of microscopic positive surgical margins and implications on post-surgical follow-up.
519 Background: Positive surgical margins (PSM) are associated with worsened survival outcomes in Renal Cell Carcinoma (RCC). Current AUA guidelines recom...
The prognostic impact of prostate-specific antigen at 6 months after post-prostatectomy radiotherapy: An individual patient data analysis of two NRG oncology randomized trials.
254 Background: We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) within 6 months of completion of salvage radiotherapy (RT)...
Molecular insights of low-PSA–expressing high-risk prostate cancer.
416 Background: Despite advances in molecular genetics and genome sequencing, identifying lethal and non-lethal forms of prostate cancer in the early stag...